New pill plus immunotherapy takes on tough melanoma
NCT ID NCT06624644
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plus pembrolizumab, or standard treatments chosen by their doctor. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LNS8801 (a tablet that targets a protein called GPER) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with advanced melanoma that has stopped responding to standard therapies.
What could go wrong
This is an early-to-mid stage trial with only 135 participants, so results may not apply to everyone. The drug may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 87535, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
UPenn
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC Newport Beach
RECRUITINGNewport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado
RECRUITINGDenver, Colorado, 80204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Anschutz
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
University of New Mexico
RECRUITINGAlbuquerque, New Mexico, 87106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••